MedGuideline Insider

H.Pylori Regimen:

Bismuth-Based Quadruple Therapy (First-line in many regions)

Duration: 14 days (preferred)
• Proton Pump Inhibitor (PPI)
• e.g., Omeprazole 20 mg BID
(Equivalent doses: Esomeprazole 20 mg BID, Lansoprazole 30 mg BID, Pantoprazole 40 mg BID)
• Bismuth Subsalicylate 524 mg QID
(or Bismuth Subcitrate 120–300 mg QID depending on formulation)
• Tetracycline 500 mg QID
• Metronidazole 500 mg TID–QID
(Higher frequency often used to overcome resistance)

🔬 Emerging Therapy for Acute PSVT Management: Etrapamil

Etrapamil, an intranasal non-dihydropyridine calcium channel blocker, is under clinical investigation for the acute conversion of Paroxysmal supraventricular tachycardia (PSVT).

Key potential advantages:
• Rapid systemic absorption via nasal mucosa
• Self-administration at symptom onset
• Reduction in emergency department utilization
• Avoidance of IV access

If Phase III data continue to demonstrate favorable safety and efficacy profiles, etrapamil may represent a paradigm shift in outpatient arrhythmia management.

Ongoing studies will clarify durability of conversion, recurrence rates, and hemodynamic tolerability.

Community Acquired Pneumonia requires Symptoms + pulmonary infiltrate on cxr to diagnose.
But sometimes pulmonary infiltrate might be missing in some cases . For eg in immunocompromised patients, patient on steroids etc unable to generate a strong cytokine response to recruit significant inflammatory cells to areas of pulmonary infection which results in minimal or no alveolar infiltrate on initial chest xray .

What to do next ?
If you have high suspicion , go for CT CHEST.

MRI breast indications:

🚨 Major Updates in Acute Ischemic Stroke Management (2026 Guidelines) 🚨

The newest stroke guidelines bring BIG changes — focusing on faster treatment, broader eligibility for reperfusion therapies, and smarter systems of care. Here are the key takeaways 👇

🧠 1. Systems of Care & Prehospital
• 🚑 Mobile Stroke Units now strongly recommended — faster thrombolysis = better outcomes
• 🏥 EMS should prioritize direct transport to thrombectomy-capable centers when LVO suspected
• 📊 Stronger emphasis on quality improvement, registries, and reducing transfer delays

💉 2. Thrombolysis (IVT) Updates
• ⭐ Tenecteplase (single bolus) endorsed as preferred alternative to alteplase
• ⏱️ Treatment window extended up to 9 hours (selected patients with advanced imaging)
• ⚡ Treat disabling deficits immediately — don’t delay for imaging inside 4.5 hours
• ❌ No thrombolysis for minor/nondisabling stroke (NIHSS ≤5) → use DAPT instead
• 🚫 No routine adjunct anticoagulants with IVT

🧬 3. Endovascular Thrombectomy (EVT) — Expanded Eligibility
• Larger infarct cores now eligible in selected patients
• 🔴 Basilar artery occlusion → strong recommendation within 24 hours
• 🧩 Selected M2 occlusions and mild prestroke disability included
• ✅ Give IVT + EVT when both indicated — don’t delay

👶 4. First Pediatric Stroke Recommendations
• MRI preferred imaging (CT if delay)
• IV thrombolysis may be considered in children with disabling deficits
• EVT reasonable in ≥6 years with LVO at experienced centers

🏥 5. Supportive Care Changes
• 🍬 Avoid intensive glucose control — treat only if >180 mg/dL
• 🩺 Avoid aggressive BP lowering after reperfusion (

3% Hypertonic Saline vs Mannitol in Severe TBI

3% hypertonic saline is at least as effective as mannitol in acutely decreasing ICP, with evidence supporting a more sustained effect and improved CPP in adults with severe TBI.

HTS may also provide superior intraoperative brain relaxation in craniotomy patients.

For pediatric patients, both agents are similarly effective.

The choice between HTS and mannitol should be individualized, taking into account patient-specific factors, clinical context, and institutional protocols.

💊ARBs of choice in different health conditions

🫀Chronic Kidney Disease (CKD)/Proteinuria: All are effective, but telmisartan, irbesartan, and losartan have strong supporting evidence.

🫀Metabolic Syndrome/Diabetes: Telmisartan is preferred due to metabolic benefits (improved insulin sensitivity).

🫀Stroke Prevention: Losartan (via LIFE study).

🫀Heart Failure: Valsartan or Candesartan.

🫀Hyperuricemia/Gout: Losartan.

SGLT2i vs GLP agonists in T2DM

SGLT2i is associated with low 5 year risk of kidney disease and acute kidney injuries as compared to GLP agonists .

Source: JAMA

Strange 🤯

Among patients with GOUT, achieving serum urate

Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout This cohort study evaluates the association between achieving a serum urate treatment target lower than 6 mg/dL and cardiovascular events among patients with gout who were newly prescribed urate-lowering treatment.

😅